Zealand Pharma applies for FDA approval for blood sugar treatment
Zealand Pharma has sent dasiglucagon, which is a treatment for low blood sugar administered through auto-injector Hypopal, for approval at the FDA.
BY KEVIN GRØNNEMANN, TRANSLATED BY CATHERINE BRETT
Years of work at Zealand Pharma have now culminated in an approval application to the FDA, which will have crucial significance for the company's future.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
